ResourcesVendorsMRIAccessoriesBlue Earth Diagnostics26 Mall Road, Suite 206, Burlington, MA, 01803eMail:Website:https://www.blueearthdiagnostics.com.LinkedIn iconLatest from Blue Earth DiagnosticsIndustry NewsBlue Earth receives approval for PET tracer for prostate cancerBy AuntMinnieEurope.com staff writersU.K.-based Blue Earth Diagnostics has received regulatory approval from the U.S. Food and Drug Administration (FDA) for its F-18 rhPSMA-7.3 PET radiotracer for detecting prostate cancer.June 1, 2023Industry NewsBlue Earth promotes PSMA radiotracer studyBy AuntMinnieEurope.com staff writersBlue Earth Diagnostics has released top-line results from its phase III trial evaluating the performance of its prostate-specific membrane antigen (PSMA) radiotracer for imaging in newly diagnosed prostate cancer.December 4, 2022Industry NewsSiemens scores access to PET data in deal with Blue EarthBy AuntMinnieEurope.com staff writersSiemens Healthineers has inked a data-sharing deal with Blue Earth Diagnostics for access to anonymized radiohybrid prostate-specific membrane antigen (PSMA) F-18 rhPSMA-7.3 clinical data and images.October 20, 2022Clinical NewsBlue Earth touts Axumin results in LancetBy AuntMinnieEurope.com staff writersBracco molecular imaging subsidiary Blue Earth Diagnostics is highlighting results of a study published in Lancet showing that postprostatectomy radiation therapy guided by the company's PET radiotracer Axumin (fluciclovine F-18) helped increase biochemical event-free survival rates in men with recurrent prostate cancer.May 27, 2021Molecular ImagingGerman study highlights promise of radiotracer for prostate imagingBy Will MortonInvestigators from the Technical University of Munich have found that an experimental radiotracer is effective when used with PET/CT for detecting biochemically recurrent prostate cancer and may change patient management.April 1, 2021Clinical NewsBlue Earth buys therapeutic rights to rhPSMA technologyBy AuntMinnieEurope.com staff writersBracco molecular imaging subsidiary Blue Earth Diagnostics has acquired exclusive, worldwide rights to therapeutic applications of radiohybrid prostate-specific membrane antigen (rhPSMA) technology developed by German radiopharmaceutical firm Scintomics and the Technical University of Munich.January 4, 2021Clinical NewsBlue Earth starts second phase III trial for PET agentBy AuntMinnieEurope.com staff writersBracco molecular imaging subsidiary Blue Earth Diagnostics has begun a second phase III clinical trial of its investigational radiohybrid PET imaging agent for prostate cancer.July 22, 2020Industry NewsBlue Earth Diagnostics brings Axumin to SlovakiaBy AuntMinnieEurope.com staff writersMolecular imaging company Blue Earth Diagnostics has completed the first commercial delivery of its Axumin (fluciclovine F-18) PET radiopharmaceutical in Slovakia.April 21, 2020Nuclear RadiologyAuntMinnieEurope.com Molecular Imaging InsiderBy Wayne ForrestJuly 21, 2019Enterprise ImagingHow to deliver on image sharing | Point-of-care ultrasound pays off | Best modality for ovarian cancerBy Philip WardJuly 9, 2019Industry NewsBracco gets set to acquire Blue Earth DiagnosticsBy Wayne ForrestContrast manufacturer Bracco Imaging is moving ahead with its plan to acquire molecular imaging company Blue Earth Diagnostics for over 390 million euros, with an additional closing adjustment estimated at 22 million euros. The deal is likely to be completed in the autumn.July 7, 2019Industry NewsBlue Earth promotes presentations at AUA 2019By AuntMinnieEurope.com staff writersMolecular imaging firm Blue Earth Diagnostics is highlighting several presentations involving its Axumin (fluciclovine F-18) PET radiopharmaceutical and its "radiohybrid" prostate-specific membrane antigen (F-18 rhPSMA-7) imaging agent at the American Urological Association (AUA) annual meeting from 3-6 May in Chicago.May 5, 2019Industry NewsBlue Earth's Axumin agent added to EAU guidelinesBy AuntMinnieEurope.com staff writersMolecular imaging firm Blue Earth Diagnostics said that its Axumin PET imaging agent has been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer.April 16, 2019Clinical NewsBlue Earth begins producing Axumin in ItalyBy AuntMinnieEurope.com staff writersMolecular imaging firm Blue Earth Diagnostics has competed the first commercial production of its Axumin PET radiopharmaceutical in Italy.February 11, 2019Genitourinary RadiologyBlue Earth signs deal with Polish firmBy AuntMinnieEurope.com staff writersMolecular imaging firm Blue Earth Diagnostics announced exclusive manufacturing and distribution agreements with radiopharmaceutical supplier Iason for its PET imaging agent Axumin (fluciclovine F-18) in Poland.June 24, 2018
